Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Stock Information for COMPASS Pathways Plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About COMPASS Pathways Plc

Enveric Biosciences Announces Reverse Stock Split
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.